Eli Lilly and Company Bucks Trend in Biotech Pursuit

Like almost every other old-line drug maker, Eli Lilly & Co. wants to get deeper into the lucrative game of selling expensive biotechnology medicines.But unlike its competitors, Lilly isn’t buying its way into biotechnology with large acquisitions. Instead, it has been trying to build a biotech-drug pipeline from within. The take-it-slow, in-house approach shows signs of paying off. But the company has yet to prove to many investors and others in the industry that it has become a major presence in biotech.

MORE ON THIS TOPIC